Publications
248
Citations
2,311
Est. group size
~32
Recurring co-author estimate
Active years
47
Publishing since 1980
John L. Hays conducts clinical cancer research, with a strong focus on gastrointestinal cancers (colorectal, pancreatic, biliary tract, hepatocellular carcinoma) as well as gynecologic cancers such as ovarian and endometrial cancer. Much of the work involves early- and mid-phase clinical trials testing new drug combinations, including targeted therapies, immune checkpoint inhibitors, and PARP/DNA-repair pathway inhibitors, alongside studies on biomarkers, patient outcomes, and clinical trial accessibility (e.g., readability of consent forms).
Publication output grew substantially from 2017 through a peak in 2023, then leveled off somewhat in 2024-2025, indicating an overall growing trend over the last decade with recent stabilization at a higher rate than earlier years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- A multi-omic analysis of EOCRC: Divergent methylation and gene expression signatures in young patients.
Journal of Clinical Oncology · 2026
- A phase 1/2 study of REGN5668, a MUC16×CD28 costimulatory bispecific antibody, in combination with other targeted therapies, in patients with recurrent ovarian or endometrial cancer: Trial in progress update.
Journal of Clinical Oncology · 2026
- Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial
Clinical Cancer Research · 2025
- Consensus Guideline for the Management of Peritoneal Mesothelioma
Annals of Surgical Oncology · 2025
- Consensus guideline for the management of peritoneal mesothelioma
Cancer · 2025
- Assessment of readability of gynecologic cancer clinical trials literature at National Cancer Institute–designated Comprehensive Cancer Centers
International Journal of Gynecological Cancer · 2025
- 10-year follow up of a phase 2 clinical trial of pembrolizumab (pembro) in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors.
Journal of Clinical Oncology · 2025
- A phase 2 study of the olaparib and AZD6738, an ATM/ATR inhibitor, in isocitrate dehydrogenase (IDH) mutant solid tumors.
Journal of Clinical Oncology · 2025
- A phase II study of peri-operative NovoTTF-200T(P) in combination with gemcitabine and nab-paclitaxel for resectable pancreatic adenocarcinoma: Big Ten Cancer Research Consortium (BTCRC-GI21-500).
Journal of Clinical Oncology · 2025
- Assessment of Readability of Informed Consent Forms of Gynecologic Cancer Clinical Trials: A (Potential) Barrier to Enrollment?
SSRN Electronic Journal · 2025
- Assessment of readability of informed consent forms of gynecologic cancer clinical trials: A (Potential) barrier to enrollment?
Gynecologic Oncology Reports · 2025
- Characterizing surveillance-associated anxiety following curative-intent surgery for gastrointestinal cancer: a mixed methods approach
Journal of Cancer Survivorship · 2025
- Impact of immune checkpoint inhibitors (ICI) in biliary tract cancer (BTC): Real-world outcomes and predictive factors.
Journal of Clinical Oncology · 2025
- Predicting immune-related adverse events (irAE) in gastrointestinal malignancies (GI-M): Tumor-specific risk factors (TS-RF), hematological markers (HM), and clinical outcomes.
Journal of Clinical Oncology · 2025
- Development of a cfDNA-based protein-informed epigenetic signature (PEp-sig) to enable biomarker-based risk stratification for pancreatic ductal adenocarcinoma (PDA).
Journal of Clinical Oncology · 2025
- Journal of Clinical Oncology×52
- Gynecologic Oncology×14
- International Journal of Gynecological Cancer×9
- Annals of Oncology×8
- Cancer Research×6
- David M. O’Malley
Medicine · The Ohio State University
- Stephanie V. Blank
Medicine · The Ohio State University
- Larry J. Copeland
Medicine · The Ohio State University
- Monica Levine
Medicine · The Ohio State University
- Laura Chambers
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile